NEVVI Medicare utilization intelligence
or

← back

Provider profile

WANG, JANET

Hematology-Oncology · NPI 1760629158 · SANTA CRUZ, CA

1
Groups
58
Codes · 2024
182,001
Disclosed services

WANG, JANET is a Hematology-Oncology in SANTA CRUZ, CA, a member of 1 medical group, who billed 58 distinct codes to Medicare Part B in 2024.

Groups: SUTTER BAY MEDICAL FOUNDATION (PALO ALTO, CA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

182,001
disclosed services
58
codes billed to Medicare Part B
Prior year · CY2023 116,884 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J3262 Injection, tocilizumab, 1 mg
J9271 Injection, pembrolizumab, 1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9299 Injection, nivolumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J1602 Injection, golimumab, 1 mg, for intravenous use
J3380 Injection, vedolizumab, intravenous, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J0897 Injection, denosumab, 1 mg
J9030 Bcg live intravesical instillation, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1459 Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg
J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2919 Injection, methylprednisolone sodium succinate, 5 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
96413 Administration of chemotherapy into vein, 1 hour or less
Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
96375 Injection of additional new drug or substance into vein
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96372 Injection of drug or substance under skin or into muscle
J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
J1750 Injection, iron dextran, 50 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9190 Injection, fluorouracil, 500 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J9045 Injection, carboplatin, 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
36591 Collection of blood sample from implanted device
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J1200 Injection, diphenhydramine hcl, up to 50 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
51720 Instillation of anti-cancer drug into bladder
J7030 Infusion, normal saline solution , 1000 cc
96374 Injection of drug or substance into vein
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96409 Administration of chemotherapy into vein using push technique
96360 Infusion into a vein for hydration, 31-60 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96411 Administration of additional new drug or substance into vein using push technique
96523 Irrigation of implanted venous access drug delivery device
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
96361 Infusion into a vein for hydration, each additional hour
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
J3490 Unclassified drugs
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99195 Drawing of blood for a medical problem
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.